|
Sample size
|
1930
|
174
|
|
Survival time (months, median [IQR])
|
24.00 [13.00, 43.00]
|
26.67 [16.93, 45.85]
|
|
Survival status (%)
| | |
|
Alive
|
994 (51.5)
|
132 (75.9)
|
|
Dead
|
936 (48.5)
|
42 (24.1)
|
|
Age (years, median [IQR])
|
63.00 [55.00, 70.00]
|
65.50 [60.00, 71.00]
|
|
Sex (%)
| | |
|
Female
|
356 (18.4)
|
34 (19.5)
|
|
Male
|
1574 (81.6)
|
140 (80.5)
|
|
Histologic grade (%)
| | |
|
Well differentiated
|
120 (6.2)
|
12 (6.9)
|
|
Moderately differentiated
|
728 (37.7)
|
68 (39.1)
|
|
Poorly differentiated
|
1051 (54.5)
|
92 (52.9)
|
|
Undifferentiated
|
31 (1.6)
|
2 (1.1)
|
|
Tumor size (%)
| | |
|
≤1 cm
|
155 (8.0)
|
7 (4.0)
|
|
1-2 cm
|
294 (15.2)
|
23 (13.2)
|
|
2-3 cm
|
356 (18.4)
|
35 (20.1)
|
|
3-4 cm
|
337 (17.5)
|
46 (26.4)
|
|
4-5 cm
|
276 (14.3)
|
23 (13.2)
|
|
> 5 cm
|
512 (26.5)
|
40 (23.0)
|
|
pStage (%)
| | |
|
I
|
373 (19.3)
|
43 (24.7)
|
|
II
|
472 (24.5)
|
63 (36.2)
|
|
III
|
986 (51.1)
|
63 (36.2)
|
|
IV
|
99 (5.1)
|
5 (2.9)
|
|
pT stage (%)
| | |
|
T1
|
389 (20.2)
|
25 (14.4)
|
|
T2
|
270 (14.0)
|
31 (17.8)
|
|
T3
|
1136 (58.9)
|
79 (45.4)
|
|
T4
|
135 (7.0)
|
39 (22.4)
|
|
pN stage (%)
| | |
|
N0
|
716 (37.1)
|
70 (40.2)
|
|
N1
|
632 (32.7)
|
35 (20.1)
|
|
N2
|
344 (17.8)
|
34 (19.5)
|
|
N3
|
238 (12.3)
|
35 (20.1)
|
|
pM stage (%)
| | |
|
M0
|
1831 (94.9)
|
169 (97.1)
|
|
M1
|
99 (5.1)
|
5 (2.9)
|
|
Chemotherapy status (%)
| | |
|
No/Unknown
|
542 (28.1)
|
40 (23.0)
|
|
Yes
|
1388 (71.9)
|
134 (77.0)
|
|
Positive LNs number (median [IQR])
|
1.00 [0.00, 3.00]
|
1.00 [0.00, 5.00]
|
|
Examined LNs number (median [IQR])
|
16.00 [10.00, 23.00]
|
30.00 [22.00, 38.00]
|
|
Ratio of metastasis LNs (median [IQR])
|
0.03 [0.00, 0.20]
|
0.05 [0.00, 0.19]
|
